The 2000 beds will be added over three years. Its a strong group – immediate improvement may come from occupancy rates going up, international patients coming back to pre-covid levels, case mix leading to improvement in margins, expansion of diagnostics business etc. Even then, given RoCE of about 14-16%, company commands a high PE (~72-75) basis trailing twelve months EPS. One wonders if the company will be able to achieve enough growth to justify these valuations.
| Subscribe To Our Free Newsletter |
